S
Sangamo Therapeutics, Inc. (SGMO)
NCM – Real vaqt narxi. Valyuta: USD
0.14
+0.02 (12.73%)
Yopilishda: May 12, 2026, 3:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.14
+0.02 (12.73%)
Yopilishda: May 12, 2026, 3:59 PM EDT
Sangamo Therapeutics, Inc. klinik tadqiqot bosqichidagi genetik dori vositalari kompaniyasi bo'lib, AQShda jiddiy kasalliklardan aziyat chekayotgan bemorlar va ularning oilalari hayotini o'zgartiradigan dori vositalarini yaratishga qaratilgan ilmiy yutuqlarni qo'llashga bag'ishlangan. Kompaniyaning klinik tadqiqot bosqichidagi mahsulot nomzodlari quyidagilardan iborat: ST-920, Fabri kasalligini davolash uchun 1/2-bosqich klinik tadqiqotda bo'lgan gen terapiyasi nomzodi; TX200, HLA-A2 mos kelmaydigan buyrak transplantatsiyasida immun vositali rad etilishini oldini olish uchun 1/2-bosqich klinik tadqiqotda bo'lgan kimera antigen retseptorlari muhandislik qilingan regulyator T-hujayralari (CAR-Treg) terapiyasi nomzodi; va SB-525, o'rtacha og'ir va og'ir A gemofiliyasini davolash uchun 3-bosqich klinik sinovda bo'lgan gen terapiyasi nomzodi. Uning preklinik rivojlanish mahsulotlari tauopatiyalar, ALS/FTD va Xantington kasalliklariga qaratilgan. Sangamo Therapeutics, Inc. Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; va Open Monoclonal Technology, Inc. bilan hamkorlik va strategik sherikliklarga ega. Kompaniya ilgari Sangamo BioSciences, Inc. nomi bilan tanilgan va 2017 yil yanvar oyida Sangamo Therapeutics, Inc. nomiga o'zgargan. Kompaniya 1995 yilda tashkil etilgan va Kaliforniyaning Richmond shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | CEO, President & Director |
| Dr. Gregory Davis Ph.D. | Head of Research & Technology |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Senior VP & Chief Development Officer |
| Mr. David Ojala | Scientist II - Discovery & Translational Research |
| Mr. Nikunj Jain | Interim CFO and Principal Financial & Accounting Officer |
| Mr. Phillip Ramsey | Chief Technical Officer |
| Mr. Scott B. Willoughby | Senior VP, Chief Legal Officer & Corporate Secretary |
| Ms. Louise Wilkie | Head of Global Corporate Communications & Investor Relations |
| Ms. Stephanie J. Seiler CLP | VP and Head of Business Development & Alliance Management |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 10-K/A | sgmo-20251231.htm |
| 2026-04-29 | 8-K | sgmo-20260428.htm |
| 2026-03-30 | 10-K | sgmo-20251231.htm |
| 2026-02-04 | 8-K | d101629d8k.htm |
| 2026-02-03 | 8-K | sgmo-20260203.htm |
| 2025-11-06 | 8-K | sgmo-20251106.htm |
| 2025-11-06 | 10-Q | sgmo-20250930.htm |
| 2025-10-29 | 8-K | sgmo-20251029.htm |
| 2025-09-30 | 8-K | sgmo-20250924.htm |
| 2025-09-11 | 8-K | sgmo-20250909.htm |